Lactobacillus rhamnosus and Lactobacillus delbrueckii ameliorate the expression of miR-155 and miR-181a in SLE patients

Vahidi, Zohreh; Samadi, Morteza; Mahmoudi, Mahmoud; Rezaieyazdi, Zahra; Sahebari, Maryam; Tabasi, Nafiseh; Esmaeili, Seyed‐Alireza; Sahebkar, Amirhossein; Rastin, Maryam

doi:10.1016/j.jff.2018.07.025

Cited by 28 publications

(23 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SARS-CoV-2 may trigger an MG crisis (111) . Restivo et al describe three patients [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] , [101] , [102] , [103] , [104] , [105] , [106] , [107] , [108] , [109] , [110] , [111] , [112] , [113] , [114] , [115] , [116] , [117] , [118] , [119] , [120] , [121] , [122] , [123] , [124] , [125] , [126] , [127] , [128] , [129] , [130] , [131]...…”

Section: Covid-19 and Autoimmunityunclassified

“…Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disorder result from a multifaceted interaction of the immune system, genetics, and environmental factors [19] , [115] , [116] . SLE pathogenesis comprises of the inherent and adaptive immune systems, autoantibodies formation, complement system activation, cytokine dysregulation (especially interferons of type I) and disrupted apoptotic clearance [117] , [118] , [119] .…”

Section: Covid-19 and Autoimmunitymentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 triggering autoimmune diseases

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Covid-19 and Autoimmunityunclassified

Section: Covid-19 and Autoimmunitymentioning

confidence: 99%

SARS-CoV-2 triggering autoimmune diseases

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…NZB/W F1 mice tend to have more diverse microbiota and enriched groups of Lactobacilli after dexamethasone treatment (Table 2) (31). The probiotics Lactobacillus rhamnosus and Lactobacillus delbrueckii were shown to downregulate the expression of miR-155 and miR-181a, which is positively correlated with the SLEDAI and kidney involvement in the PBMCs of SLE patients (66,67). Lactobacillales has been reported to be markedly depleted in MRL/lpr mice, and increasing Lactobacillales can correct the leaky gut, promote IL-10, improve renal function, and prolong mouse survival (Table 2) (61).…”

Section: Specific Bacterial Populations and Pathways Linked To The Microbiota And Slementioning

confidence: 99%

Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention

et al. 2021

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), often considered the prototype of autoimmune diseases, is characterized by over-activation of the autoimmune system with abnormal functions of innate and adaptive immune cells and the production of a large number of autoantibodies against nuclear components. Given the highly complex and heterogeneous nature of SLE, the pathogenesis of this disease remains incompletely understood and is presumed to involve both genetic and environmental factors. Currently, disturbance of the gut microbiota has emerged as a novel player involved in the pathogenesis of SLE. With in-depth research, the understanding of the intestinal bacteria-host interaction in SLE is much more comprehensive. Recent years have also seen an increase in metabolomics studies in SLE with the attempt to identify potential biomarkers for diagnosis or disease activity monitoring. An intricate relationship between gut microbiome changes and metabolic alterations could help explain the mechanisms by which gut bacteria play roles in the pathogenesis of SLE. Here, we review the role of microbiota dysbiosis in the aetiology of SLE and how intestinal microbiota interact with the host metabolism axis. A proposed treatment strategy for SLE based on gut microbiome (GM) regulation is also discussed in this review. Increasing our understanding of gut microbiota and their function in lupus will provide us with novel opportunities to develop effective and precise diagnostic strategies and to explore potential microbiota-based treatments for patients with lupus.

show abstract

“…To date, the management and treatment strategies for SLE have been primarily dependent on antimalarials, steroidal, and non-steroidal immunosuppressive drugs and antiinflammatory agents. 9,[48][49][50][51] However, despite significant achievements in SLE management from the clinical perspective, almost all available large-scale randomized trials have reported the medical modalities as ineffective in SLE patients, being also often accompanied with substantial toxicities. 8,52 Thus, developing novel therapeutic strategies with enhanced efficacy and less toxicity than the current treatment standards are urgently required for SLE patients and others who suffer from severe autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

“…To date, the management and treatment strategies for SLE have been primarily dependent on antimalarials, steroidal, and non‐steroidal immunosuppressive drugs and anti‐inflammatory agents 9,48–51 . However, despite significant achievements in SLE management from the clinical perspective, almost all available large‐scale randomized trials have reported the medical modalities as ineffective in SLE patients, being also often accompanied with substantial toxicities 8,52 .…”

Section: Introductionmentioning

confidence: 99%

The immunomodulatory effects of mesenchymal stromal cell‐based therapy in human and animal models of systemic lupus erythematosus

et al. 2020

Self Cite

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune inflammatory disease with no absolute cure. Although the exact etiopathogenesis of SLE is still enigmatic, it has been well demonstrated that a combination of genetic predisposition and environmental factors trigger a disturbance in immune responses and thereby participate in the development of this condition. Almost all available therapeutic strategies in SLE are primarily based on the administration of immunosuppressive drugs and are not curative. Mesenchymal stromal cells (MSCs) are a subset of non-hematopoietic adult stem cells that can be isolated from many adult tissues and are increasingly recognized as immune response modulating agents. MSC-mediated inhibition of immune responses is a complex mechanism that involves almost every aspect of the immune response. MSCs suppress the maturation of antigen-presenting cells (DC and MQ), proliferation of T cells (Th1, T17, and Th2), proliferation and immunoglobulin production of B cells, the cytotoxic activity of CTL and NK cells in addition to increasing regulatory cytokines (TGF-β and IL10), and decreasing inflammatory cytokines (IL17, INF-Υ, TNF-α, and IL12) levels. MSCs have shown encouraging results in the treatment of several autoimmune diseases, in particular SLE. This report aims to review the beneficial and therapeutic properties of MSCs; it also focuses on the results of animal model studies, preclinical studies, and clinical trials of MSC therapy in SLE from the immunoregulatory aspect.

show abstract

Lactobacillus rhamnosus and Lactobacillus delbrueckii ameliorate the expression of miR-155 and miR-181a in SLE patients

Cited by 28 publications

References 56 publications

SARS-CoV-2 triggering autoimmune diseases

SARS-CoV-2 triggering autoimmune diseases

Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention

The immunomodulatory effects of mesenchymal stromal cell‐based therapy in human and animal models of systemic lupus erythematosus

Contact Info

Product

Resources

About